Tirzepatide

Tirzepatide (20 mg) is a higher-dose format of the dual GIP/GLP-1 receptor agonist, designed for extended research protocols requiring larger total compound quantities. The 20 mg format supports dose-response characterization studies, chronic multi-week administration protocols, and comprehensive metabolic phenotyping experiments where multiple biomarker endpoints are measured simultaneously. Research applications include investigation of dose-dependent effects on beta-cell function (measured by HOMA-B and C-peptide responses), adipose tissue gene expression profiling, hepatic lipid metabolism quantification via imaging and biochemical assays, and long-term body composition monitoring through DEXA and MRI-based approaches. The larger format also facilitates pharmacokinetic studies and enables multi-condition experimental designs within a single research campaign.